We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis to Pay Up to $770 Million for Cadent Therapeutics, Enhancing Neuropsychiatric Pipeline
Novartis to Pay Up to $770 Million for Cadent Therapeutics, Enhancing Neuropsychiatric Pipeline
Novartis has agreed to buy Cambridge, Mass.-based Cadent Therapeutics for a possible $770 million, expanding its pipeline of treatments for cognitive and mood disorders.